ANDOZINE 2 %

Q-0209-108

Injectable solution

Sedative, tranquilizer, analgesic and muscle relaxant

Fórmula

Each ml contains::	
Xilacina base	20 mg
Vehicle .	1 ml

Uso en especies

Bovines, Equines, Ovines, Caprines, Dogs, Cats

INDICATIONS AND USES

andozine ® 2 % s a sedative, tranquilizer, analgesic and muscle relaxant indicated for contention in diagnosis exams, painful procedures, animal transport, healing, dentistry, and in major and minor surgeries in bovines, equines, ovines, caprines, dogs and cats.

CLINICAL PHARMACOLOGY:

DRUG KINETIC: Xylazine, after intramuscular administration, is rapidly absorbed, it's an adrenergic alpha-2 agonist drug derived from tiacin, rapidly distributing in CNS level. Its metabolism takes place on a hepatic level where it undergoes an extensive degradation and its metabolites are excreted in urine.

Pharmacodynamics: It acts on the central nervous system by inhibiting calcium intake on a pre-synaptic level, thereby decreasing the release of neurotransmitters such as dopamine and norepinephrine, producing sedation and analgesia. It also acts upon some cholinergic, serotoninergic, H2 histaminic and opiate receptors.
At peripheral nervous system level, it produces a vasoconstrictor effect and therefore hypertension, increase in the afterload and increase of cerebral perfusion, in addition to a decrease in the release of insulin, therefore hyperglycemia, apart from a certain degree of polyuria, decrease in gastrointestinal motility and a tendency towards gastric dilation.
Muscle relaxation is produced by the inhibition of interneuronal transmission in the spinal cord. It also produces selective activation of the parasympathetic nervous system and sympathetic nervous system inhibition, as well as depression of the vasomotor center in the brainstem and increase in vagal and vessel receptor activity at central level.
Its effects on the cardiovascular system are characterized initially by an increase in arterial pressure, followed by a longer period of hypotension and bradycardia.
It also sensitizes the myocardial to catecholamines, predisposing the appearance of spontaneous arrhythmias.
In some patients, a minor or no decrease in frequency and depth of breathing is produced, even though it produces relaxation of the larynx and suppresses the cough reflex.

DOSAGE:

Dogs	
Sedative dose	.25 to 0.5 mg/kg body weight, for every kilogram of body weight by (I.M. injection) 0.25 to 0.5 ml for every 10 kilograms of body weight.
Tranquilizing dose	(1.0 mg for every kilogram of body weight by I.M. injection) 0.5 ml for every 10 kilograms of body weight.

Equines	
Sedative dose	(1.1 mg for every kilogram of body weight by I.V. injection) 5.5 ml for every 100 kilograms of body weight.
Sedative dose	(2.2 mg for every kilogram of body weight by I.M. injection) 11.0 mlfor every 100 kilograms of body weight

ANDOZINE 2 %

Q-0209-108

Cats	
Sedative dose	0.25 to 0.5 mg/kg body weight, for every kilogram of body weight by I.M. injection) 0.25 to 0.5 ml for every 10 kilograms of body weight.
Tranquilizing dose:	(1.0 mg for every kilogram of body weight by I.M. injection) 0.5 ml for every 10 kilograms of body weight.

Ovines and caprines
(0.05 to 0.10 mg for every kilogram of body weight by I.V. injection) 0.125 to 0.25 ml for every 50 kilograms of body weight. The routine use of anticholinergics is appropriate by way of minimizing undesirable cardiovascular effects.

ANTIDOTE:

The effects of xylazine can be reversed with 4- aminopiperidine or with yohimbine hydrochloride. Both drugs can be administered intravenously in doses of 0.12 mg for every kilogram of body weight and 0.1 to 0.3 mg for every kilogram of body weight respectively.

ROUTE OF ADMINISTRATION:

Dogs: Intramuscular and intravenous.
Cats: Intramuscular.
Bovines: Intramuscular and intravenous.
Equines: Intramuscular and intravenous.
Ovines y caprines: Intravenous.

WARNING:

andozine ® 2 % must not be administered in the last month of pregnancy due to risk of premature birth induction.
Do not administer on dogs or cats with esophageal obstruction or stomach torsion.
Do not administer on hypertensive patients. Its use must be avoided on patients with a history of ventricular arrhythmia, cardiac insufficiency, hepatic and renal illness, respiratory dysfunction, seizures, cachectic states, and severe dehydration states.
Store at room temperature at no more than 30ºC in a dry place.
Do not leave within reach of children.
Sold only by quantified prescription.
For exclusive use of veterinarians.

DRUG INTERACTIONS:

Do not administer concurrently with epinephrine.

WITHDRAWAL PERIOD:

Do not use this product 3 days before slaughter of animals for human consumption
Do not consume the milk of medicated animals until 5 days after administration.
Not to be administered to equines intended for human consumption

PRESENTATION

Jar with: 25 ml